Biologic Drugs

Rentschler Biopharma, Ikarovec Collaboration Set to Speed Up Ophthalmic Therapy Development

June 01, 2023

A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.

Ramping Up Nucleic Acid Therapy Development

May 03, 2023

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.

E&L Analytical Testing Considerations

May 03, 2023

E&L analytical testing methods can be determined through pointed consideration of the differences small- and large-molecule drug products.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

May 02, 2023

In this episode, Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Formulating Drugs for Continuous Processing

April 03, 2023

Despite the advantages intensified processes can offer developers, there are still some obstacles to overcome before broader application of new technologies will be implemented.

Accepting Alternative Approaches to Freeze Drying

April 02, 2023

Alternative approaches to freeze-drying are gaining popularity and will help to overcome some of the challenges associated with conventional lyophilization.

Considerations for Analytical Testing for E&L

April 02, 2023

Considering the differences between small- and large-molecule drug products can help determine analytical testing methods for E&L.

Takeda Gets Approval in Japan for Entyvio Subcutaneous Injection

March 30, 2023

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.

Sandoz to Build New Biologics Production Facility in Slovenia

March 17, 2023

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Catalent Licenses Bhami Research Laboratory Technology for Biologics Formulation Development

March 17, 2023

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.